Intra-Cellular Therapies ... (ITCI)
NASDAQ: ITCI
· Real-Time Price · USD
131.87
0.00 (0.00%)
At close: Apr 01, 2025, 3:59 PM
0.00% (1D)
| Bid | 131.83 |
| Market Cap | 14.05B |
| Revenue (ttm) | 680.64M |
| Net Income (ttm) | -74.68M |
| EPS (ttm) | -0.73 |
| PE Ratio (ttm) | -180.64383561643837 |
| Forward PE | 30.6 |
| Analyst | Hold |
| Ask | 131.92 |
| Volume | 16,042,154 |
| Avg. Volume (20D) | 3,621,742 |
| Open | 131.87 |
| Previous Close | 131.87 |
| Day's Range | 131.87 - 131.87 |
| 52-Week Range | 64.09 - 131.98 |
| Beta | 0.46 |
About ITCI
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITCI
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITCI stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts7 months ago
+34.07%
Intra-Cellular Therapies shares are trading higher...
Unlock content with
Pro Subscription
9 months ago
+11.36%
Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.
